Emily M. Leproust, Chief Executive Officer of Twist Bioscience (TWST), has filed 87 Form 4 transactions across two companies, with a total sell value of $103,057,493.68 and zero buy value. The pattern is entirely one-directional: every recent transaction is an open-market sale (code S), with 25 sales in the most recent period. There are no open-market purchases, no grants, and no option exercises in the recent data, which means the selling is not tied to compensation mechanics or tax withholding.
The recent sales cluster in September and October 2026, with the largest single transaction on October 2, 2026, valued at $8,638,798.62. That sale dwarfs the surrounding activity. On September 17, 2026, Leproust sold $2,325,245.33 and $1,803,715.32 in two separate transactions, plus two smaller sales totaling $558,322.55. September 24 saw a series of ten sales ranging from $2,920 to $435,449.78, and October 5 produced eight sales between $9,335.50 and $368,805.74. The smallest recent sale was $2,920 on September 24, and the largest was the October 2 block.
The concentration in TWST is total. All 25 recent trades are in that single ticker, and the dollar values show no taper. The selling is steady across multiple dates, with no gaps longer than a few days between September 17 and October 5. The absence of any buy-side activity, combined with the size and frequency of the sales, gives a clear picture of a CEO who is consistently reducing her position in Twist Bioscience through open-market transactions.
AI-assisted summary